Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 315

1.

Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma.

Hartmann S, Döring C, Vucic E, Chan FC, Ennishi D, Tousseyn T, de Wolf-Peeters C, Perner S, Wlodarska I, Steidl C, Gascoyne RD, Hansmann ML.

Br J Haematol. 2015 May;169(3):415-22. doi: 10.1111/bjh.13310. Epub 2015 Feb 2.

PMID:
25644177
2.

Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma--endpoints of a spectrum of one disease?

Hartmann S, Döring C, Jakobus C, Rengstl B, Newrzela S, Tousseyn T, Sagaert X, Ponzoni M, Facchetti F, de Wolf-Peeters C, Steidl C, Gascoyne R, Küppers R, Hansmann ML.

PLoS One. 2013 Nov 11;8(11):e78812. doi: 10.1371/journal.pone.0078812. eCollection 2013.

3.

Macrophages in T cell/histiocyte rich large B cell lymphoma strongly express metal-binding proteins and show a bi-activated phenotype.

Hartmann S, Tousseyn T, Döring C, Flüchter P, Hackstein H, Herreman A, Ponzoni M, de Wolf-Peeters C, Facchetti F, Gascoyne RD, Küppers R, Steidl C, Hansmann ML.

Int J Cancer. 2013 Dec 1;133(11):2609-18. doi: 10.1002/ijc.28273. Epub 2013 Jun 29.

4.

Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders.

Morscio J, Dierickx D, Ferreiro JF, Herreman A, Van Loo P, Bittoun E, Verhoef G, Matthys P, Cools J, Wlodarska I, De Wolf-Peeters C, Sagaert X, Tousseyn T.

Am J Transplant. 2013 May;13(5):1305-16. doi: 10.1111/ajt.12196. Epub 2013 Mar 14.

5.

Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors.

Dierickx D, Tousseyn T, Sagaert X, Fieuws S, Wlodarska I, Morscio J, Brepoels L, Kuypers D, Vanhaecke J, Nevens F, Verleden G, Van Damme-Lombaerts R, Renard M, Pirenne J, De Wolf-Peeters C, Verhoef G.

Leuk Lymphoma. 2013 Nov;54(11):2433-40. doi: 10.3109/10428194.2013.780655. Epub 2013 Apr 9.

PMID:
23442063
6.

Clinicopathological characteristics of posttransplant lymphoproliferative disorders of T-cell origin: single-center series of nine cases and meta-analysis of 147 reported cases.

Herreman A, Dierickx D, Morscio J, Camps J, Bittoun E, Verhoef G, De Wolf-Peeters C, Sagaert X, Tousseyn T.

Leuk Lymphoma. 2013 Oct;54(10):2190-9. doi: 10.3109/10428194.2013.775436. Epub 2013 Mar 27.

PMID:
23402267
7.

The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder.

Dierickx D, Tousseyn T, Requilé A, Verscuren R, Sagaert X, Morscio J, Wlodarska I, Herreman A, Kuypers D, Van Cleemput J, Nevens F, Dupont L, Uyttebroeck A, Pirenne J, De Wolf-Peeters C, Verhoef G, Brepoels L, Gheysens O.

Haematologica. 2013 May;98(5):771-5. doi: 10.3324/haematol.2012.074500. Epub 2012 Oct 12.

8.

Recurrent breakpoints in 14q32.13/TCL1A region in mature B-cell neoplasms with villous lymphocytes.

Urbankova H, Baens M, Michaux L, Tousseyn T, Rack K, Katrincsakova B, Ferreiro JF, van Loo P, de Kelver W, Dierickx D, Demuynck H, Delannoy A, Verschuere J, Jarošová M, de Wolf-Peeters C, Vandenberghe P, Wlodarska I.

Leuk Lymphoma. 2012 Dec;53(12):2449-55. doi: 10.3109/10428194.2012.690098.

PMID:
22553924
9.

T cell/histiocyte-rich large B-cell lymphoma: an update on its biology and classification.

Tousseyn T, De Wolf-Peeters C.

Virchows Arch. 2011 Dec;459(6):557-63. doi: 10.1007/s00428-011-1165-z. Epub 2011 Nov 12. Review.

PMID:
22081105
10.

t(X;14)(p11.4;q32.33) is recurrent in marginal zone lymphoma and up-regulates GPR34.

Baens M, Finalet Ferreiro J, Tousseyn T, Urbankova H, Michaux L, de Leval L, Dierickx D, Wolter P, Sagaert X, Vandenberghe P, De Wolf-Peeters C, Wlodarska I.

Haematologica. 2012 Feb;97(2):184-8. doi: 10.3324/haematol.2011.052639. Epub 2011 Nov 4.

11.

Management of posttransplant lymphoproliferative disorders following solid organ transplant: an update.

Dierickx D, Tousseyn T, De Wolf-Peeters C, Pirenne J, Verhoef G.

Leuk Lymphoma. 2011 Jun;52(6):950-61. doi: 10.3109/10428194.2011.557453. Epub 2011 Feb 21. Review.

PMID:
21338285
12.

JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma.

Van Roosbroeck K, Cox L, Tousseyn T, Lahortiga I, Gielen O, Cauwelier B, De Paepe P, Verhoef G, Marynen P, Vandenberghe P, De Wolf-Peeters C, Cools J, Wlodarska I.

Blood. 2011 Apr 14;117(15):4056-64. doi: 10.1182/blood-2010-06-291310. Epub 2011 Feb 15.

PMID:
21325169
13.

Differential expression of NF-kappaB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism.

Hamoudi RA, Appert A, Ye H, Ruskone-Fourmestraux A, Streubel B, Chott A, Raderer M, Gong L, Wlodarska I, De Wolf-Peeters C, MacLennan KA, de Leval L, Isaacson PG, Du MQ.

Leukemia. 2010 Aug;24(8):1487-97. doi: 10.1038/leu.2010.118. Epub 2010 Jun 3.

PMID:
20520640
14.

ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions.

Van Roosbroeck K, Cools J, Dierickx D, Thomas J, Vandenberghe P, Stul M, Delabie J, De Wolf-Peeters C, Marynen P, Wlodarska I.

Haematologica. 2010 Mar;95(3):509-13. doi: 10.3324/haematol.2009.014761.

15.

Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms.

Piva R, Agnelli L, Pellegrino E, Todoerti K, Grosso V, Tamagno I, Fornari A, Martinoglio B, Medico E, Zamò A, Facchetti F, Ponzoni M, Geissinger E, Rosenwald A, Müller-Hermelink HK, De Wolf-Peeters C, Piccaluga PP, Pileri S, Neri A, Inghirami G.

J Clin Oncol. 2010 Mar 20;28(9):1583-90. doi: 10.1200/JCO.2008.20.9759. Epub 2010 Feb 16.

PMID:
20159827
16.

Comparative expressed sequence hybridization studies of t(11;18)(q21;q21)-positive and -negative gastric MALT lymphomas reveal both unique and overlapping gene programs.

Sagaert X, Tousseyn T, Vanhentenrijk V, Van Loo P, Baens M, Marynen P, De Hertogh G, Geboes K, De Wolf-Peeters C.

Mod Pathol. 2010 Mar;23(3):458-69. doi: 10.1038/modpathol.2009.182. Epub 2010 Jan 15.

17.

T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response.

Van Loo P, Tousseyn T, Vanhentenrijk V, Dierickx D, Malecka A, Vanden Bempt I, Verhoef G, Delabie J, Marynen P, Matthys P, De Wolf-Peeters C.

Haematologica. 2010 Mar;95(3):440-8. doi: 10.3324/haematol.2009.009647. Epub 2009 Oct 1.

18.

Recipient-derived chronic lymphocytic leukaemia diagnosed shortly after kidney transplantation on protocol biopsy.

Dierickx D, De Rycke A, Vandenberghe P, Janssens A, Lerut E, De Wolf-Peeters C, Verhoef G, Evenepoel P.

Nephrol Dial Transplant. 2009 Dec;24(12):3886-90. doi: 10.1093/ndt/gfp444. Epub 2009 Sep 3.

PMID:
19729460
19.

(18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model.

Brepoels L, Stroobants S, Verhoef G, De Groot T, Mortelmans L, De Wolf-Peeters C.

J Nucl Med. 2009 Jul;50(7):1102-9. doi: 10.2967/jnumed.109.062208. Epub 2009 Jun 12.

20.

Auto-ubiquitination-induced degradation of MALT1-API2 prevents BCL10 destabilization in t(11;18)(q21;q21)-positive MALT lymphoma.

Noels H, Somers R, Liu H, Ye H, Du MQ, De Wolf-Peeters C, Marynen P, Baens M.

PLoS One. 2009;4(3):e4822. doi: 10.1371/journal.pone.0004822. Epub 2009 Mar 12.

21.

Secondary central nervous system involvement in cyclin D1-negative mantle cell lymphoma.

Dierickx D, Wlodarska I, Vanhentenrijk V, De Wolf-Peeters C, Devos T, Delforge M, Janssens A, Maertens J, Thomas J, Verhoef G.

Leuk Lymphoma. 2008 Dec;49(12):2365-6. doi: 10.1080/10428190802464737. No abstract available.

PMID:
19052986
22.

Allogeneic bone marrow transplantation and donor lymphocyte infusion in a mouse model of irradiation-induced myelodysplastic/myeloproliferation syndrome (MD/MPS): evidence for a graft-versus-MD/MPS effect.

Sprangers B, Van Wijmeersch B, Luyckx A, Sagaert X, De Somer L, Rutgeerts O, Lenaerts C, Landuyt W, Boeckx N, Dubois B, De Wolf-Peeters C, Waer M, Billiau AD.

Leukemia. 2009 Feb;23(2):340-9. doi: 10.1038/leu.2008.298. Epub 2008 Nov 6.

PMID:
18987665
23.

Positron emission tomography in mantle cell lymphoma.

Brepoels L, Stroobants S, De Wever W, Dierickx D, Vandenberghe P, Thomas J, Mortelmans L, Verhoef G, De Wolf-Peeters C.

Leuk Lymphoma. 2008 Sep;49(9):1693-701. doi: 10.1080/10428190802216707.

PMID:
18798104
24.

Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.

Vanden Bempt I, Van Loo P, Drijkoningen M, Neven P, Smeets A, Christiaens MR, Paridaens R, De Wolf-Peeters C.

J Clin Oncol. 2008 Oct 20;26(30):4869-74. doi: 10.1200/JCO.2007.13.4296. Epub 2008 Sep 15.

PMID:
18794552
25.

NOTCH2 mutations in marginal zone lymphoma.

Trøen G, Wlodarska I, Warsame A, Hernández Llodrà S, De Wolf-Peeters C, Delabie J.

Haematologica. 2008 Jul;93(7):1107-9. doi: 10.3324/haematol.11635. Epub 2008 May 27. No abstract available.

26.

Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas.

Wlodarska I, Dierickx D, Vanhentenrijk V, Van Roosbroeck K, Pospísilová H, Minnei F, Verhoef G, Thomas J, Vandenberghe P, De Wolf-Peeters C.

Blood. 2008 Jun 15;111(12):5683-90. doi: 10.1182/blood-2007-10-118794. Epub 2008 Apr 7.

PMID:
18391076
27.

Occurrence of autoimmunity after xenothymus transplantation in T-cell-deficient mice depends on the thymus transplant technique.

Devos T, Sprangers B, Lin Y, Li S, Yan Y, Landuyt W, Lenaerts C, Rutgeerts O, Goebels J, Bullens D, De Wolf-Peeters C, Mathieu C, Waer M, Billiau AD.

Transplantation. 2008 Feb 27;85(4):640-4. doi: 10.1097/TP.0b013e3181613f0c.

PMID:
18347545
28.

The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity.

Vanden Bempt I, Drijkoningen M, De Wolf-Peeters C.

Curr Opin Oncol. 2007 Nov;19(6):552-7. Review.

PMID:
17906451
29.

Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma?

Uyttebroeck A, Vanhentenrijk V, Hagemeijer A, Boeckx N, Renard M, Wlodarska I, Vandenberghe P, Depaepe P, De Wolf-Peeters C.

Leuk Lymphoma. 2007 Sep;48(9):1745-54.

PMID:
17786710
30.

Hodgkin lymphoma: Response assessment by revised International Workshop Criteria.

Brepoels L, Stroobants S, De Wever W, Spaepen K, Vandenberghe P, Thomas J, Uyttebroeck A, Mortelmans L, De Wolf-Peeters C, Verhoef G.

Leuk Lymphoma. 2007 Aug;48(8):1539-47.

PMID:
17701585
31.

Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria.

Brepoels L, Stroobants S, De Wever W, Spaepen K, Vandenberghe P, Thomas J, Uyttebroeck A, Mortelmans L, De Wolf-Peeters C, Verhoef G.

Leuk Lymphoma. 2007 Aug;48(8):1522-30.

PMID:
17701583
32.

Freund's complete adjuvant induces arthritis in mice lacking a functional interferon-gamma receptor by triggering tumor necrosis factor alpha-driven osteoclastogenesis.

Geboes L, De Klerck B, Van Balen M, Kelchtermans H, Mitera T, Boon L, De Wolf-Peeters C, Matthys P.

Arthritis Rheum. 2007 Aug;56(8):2595-607.

33.

The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor /progesterone receptor /HER-2 breast carcinomas.

Verlinden L, Vanden Bempt I, Eelen G, Drijkoningen M, Verlinden I, Marchal K, De Wolf-Peeters C, Christiaens MR, Michiels L, Bouillon R, Verstuyf A.

Cancer Res. 2007 Jul 15;67(14):6574-81.

34.

Interstitial del(14)(q) involving IGH: a novel recurrent aberration in B-NHL.

Pospisilova H, Baens M, Michaux L, Stul M, Van Hummelen P, Van Loo P, Vermeesch J, Jarosova M, Zemanova Z, Michalova K, Van den Berghe I, Alexander HD, Hagemeijer A, Vandenberghe P, Cools J, De Wolf-Peeters C, Marynen P, Wlodarska I.

Leukemia. 2007 Sep;21(9):2079-83. Epub 2007 May 24. No abstract available.

PMID:
17525729
35.

CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease.

Fevery S, Billiau AD, Sprangers B, Rutgeerts O, Lenaerts C, Goebels J, Landuyt W, Kasran A, Boon L, Sagaert X, De Wolf-Peeters C, Waer M, Vandenberghe P.

Leukemia. 2007 Jul;21(7):1451-9. Epub 2007 May 17.

PMID:
17508005
36.

A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation.

Martín-Subero JI, Ibbotson R, Klapper W, Michaux L, Callet-Bauchu E, Berger F, Calasanz MJ, De Wolf-Peeters C, Dyer MJ, Felman P, Gardiner A, Gascoyne RD, Gesk S, Harder L, Horsman DE, Kneba M, Küppers R, Majid A, Parry-Jones N, Ritgen M, Salido M, Solé F, Thiel G, Wacker HH, Oscier D, Wlodarska I, Siebert R.

Leukemia. 2007 Jul;21(7):1532-44. Epub 2007 May 10.

PMID:
17495977
37.

The dynamics of the B follicle: understanding the normal counterpart of B-cell-derived malignancies.

Sagaert X, Sprangers B, De Wolf-Peeters C.

Leukemia. 2007 Jul;21(7):1378-86. Epub 2007 May 10. Review.

PMID:
17495967
38.

Effect of corticosteroids on 18F-FDG uptake in tumor lesions after chemotherapy.

Brepoels L, Stroobants S, Vandenberghe P, Spaepen K, Dupont P, Nuyts J, Bormans G, Mortelmans L, Verhoef G, De Wolf-Peeters C.

J Nucl Med. 2007 Mar;48(3):390-7.

39.

The pathogenesis of MALT lymphomas: where do we stand?

Sagaert X, De Wolf-Peeters C, Noels H, Baens M.

Leukemia. 2007 Mar;21(3):389-96. Epub 2007 Jan 18. Review.

PMID:
17230229
40.

Splenic marginal zone lymphoma-like features in API2-MALT1 transgenic mice that are exposed to antigenic stimulation.

Sagaert X, Theys T, De Wolf-Peeters C, Marynen P, Baens M.

Haematologica. 2006 Dec;91(12):1693-6.

41.

Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities.

De Paepe P, De Wolf-Peeters C.

Leukemia. 2007 Jan;21(1):37-43. Epub 2006 Oct 12. Review.

PMID:
17039226
42.

Relationship between classic Hodgkin lymphoma and overlapping large cell lymphoma investigated by comparative expressed sequence hybridization expression profiling.

Vanhentenrijk V, Vanden Bempt I, Dierickx D, Verhoef G, Wlodarska I, De Wolf-Peeters C.

J Pathol. 2006 Oct;210(2):155-62.

PMID:
16874743
43.

Aggressive systemic mastocytosis complicated by protein-losing enteropathy.

Mickys U, Barakauskiene A, De Wolf-Peeters C, Geboes K, De Hertogh G.

Dig Liver Dis. 2007 Jul;39(7):693-7. Epub 2006 Jul 14.

PMID:
16843741
44.

Selective expansion of marginal zone B cells in Emicro-API2-MALT1 mice is linked to enhanced IkappaB kinase gamma polyubiquitination.

Baens M, Fevery S, Sagaert X, Noels H, Hagens S, Broeckx V, Billiau AD, De Wolf-Peeters C, Marynen P.

Cancer Res. 2006 May 15;66(10):5270-7.

45.

Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.

Sagaert X, de Paepe P, Libbrecht L, Vanhentenrijk V, Verhoef G, Thomas J, Wlodarska I, De Wolf-Peeters C.

J Clin Oncol. 2006 Jun 1;24(16):2490-7. Epub 2006 Apr 24.

PMID:
16636337
46.

Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma.

Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin PJ, de Wolf-Peeters C, MacLennan K, Staab-Renner E, Kalmus J, Schott A, Teodorovic I, Negrouk A, van Glabbeke M, Marcus R.

J Clin Oncol. 2006 Apr 1;24(10):1590-6.

PMID:
16575010
47.

Comparative expressed sequence hybridization reveals differential gene expression in morphological breast cancer subtypes.

Vanden Bempt I, Vanhentenrijk V, Drijkoningen M, De Wolf-Peeters C.

J Pathol. 2006 Mar;208(4):486-94.

PMID:
16402338
48.

MALT1 and BCL10 aberrations in MALT lymphomas and their effect on the expression of BCL10 in the tumour cells.

Sagaert X, Laurent M, Baens M, Wlodarska I, De Wolf-Peeters C.

Mod Pathol. 2006 Feb;19(2):225-32.

49.

Organotypic epithelial raft cultures as a model for evaluating compounds against alphaherpesviruses.

Andrei G, van den Oord J, Fiten P, Opdenakker G, De Wolf-Peeters C, De Clercq E, Snoeck R.

Antimicrob Agents Chemother. 2005 Nov;49(11):4671-80.

50.

Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas.

De Paepe P, Achten R, Verhoef G, Wlodarska I, Stul M, Vanhentenrijk V, Praet M, De Wolf-Peeters C.

J Clin Oncol. 2005 Oct 1;23(28):7060-8. Epub 2005 Aug 29.

PMID:
16129841

Supplemental Content

Loading ...
Support Center